{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T17:43:10Z","timestamp":1792258990426,"version":"4.4.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2009,7,10]],"date-time":"2009-07-10T00:00:00Z","timestamp":1247184000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Exp Metastasis"],"published-print":{"date-parts":[[2009,10]]},"DOI":"10.1007\/s10585-009-9279-2","type":"journal-article","created":{"date-parts":[[2009,7,9]],"date-time":"2009-07-09T16:35:24Z","timestamp":1247157324000},"page":"797-808","source":"Crossref","is-referenced-by-count":15,"title":["Enhanced expression and shedding of receptor activator of NF-\u03baB ligand during tumor\u2013bone interaction potentiates mammary tumor-induced osteolysis"],"prefix":"10.1007","volume":"26","author":[{"given":"Kalyan C.","family":"Nannuru","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuru","family":"Futakuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anguraj","family":"Sadanandam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas J.","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle L.","family":"Varney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen J.","family":"Myers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaodong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric G.","family":"Marcusson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rakesh K.","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2009,7,10]]},"reference":[{"issue":"2","key":"9279_CR1","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3322\/CA.2007.0010","volume":"58","author":"A Jemal","year":"2008","unstructured":"Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T et al (2008) Cancer statistics, 2008. CA Cancer J Clin 58(2):71\u201396","journal-title":"CA Cancer J Clin"},{"issue":"8","key":"9279_CR2","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1038\/nrc867","volume":"2","author":"GR Mundy","year":"2002","unstructured":"Mundy GR (2002) Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2(8):584\u2013593","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"9279_CR3","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1677\/erc.0.0060333","volume":"6","author":"BF Boyce","year":"1999","unstructured":"Boyce BF, Yoneda T, Guise TA (1999) Factors regulating the growth of metastatic cancer in bone. Endocr Relat Cancer 6(3):333\u2013347","journal-title":"Endocr Relat Cancer"},{"issue":"8 Suppl","key":"9279_CR4","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1002\/(SICI)1097-0142(19971015)80:8+<1588::AID-CNCR9>3.0.CO;2-G","volume":"80","author":"RE Coleman","year":"1997","unstructured":"Coleman RE (1997) Skeletal complications of malignancy. Cancer 80(8 Suppl):1588\u20131594","journal-title":"Cancer"},{"issue":"3 Suppl","key":"9279_CR5","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1002\/cncr.11132","volume":"97","author":"SM Kakonen","year":"2003","unstructured":"Kakonen SM, Mundy GR (2003) Mechanisms of osteolytic bone metastases in breast carcinoma. Cancer 97(3 Suppl):834\u2013839","journal-title":"Cancer"},{"issue":"16","key":"9279_CR6","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1056\/NEJMra030831","volume":"350","author":"GD Roodman","year":"2004","unstructured":"Roodman GD (2004) Mechanisms of bone metastasis. N Engl J Med 350(16):1655\u20131664","journal-title":"N Engl J Med"},{"issue":"2","key":"9279_CR7","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S0002-9440(10)64556-7","volume":"157","author":"DL Lacey","year":"2000","unstructured":"Lacey DL, Tan HL, Lu J, Kaufman S, Van G, Qiu W et al (2000) Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo. Am J Pathol 157(2):435\u2013448","journal-title":"Am J Pathol"},{"issue":"4","key":"9279_CR8","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/s10555-006-9021-3","volume":"25","author":"WC Dougall","year":"2006","unstructured":"Dougall WC, Chaisson M (2006) The RANK\/RANKL\/OPG triad in cancer-induced bone diseases. Cancer Metastasis Rev 25(4):541\u2013549","journal-title":"Cancer Metastasis Rev"},{"issue":"1","key":"9279_CR9","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1186\/1471-2407-7-148","volume":"7","author":"C Morrissey","year":"2007","unstructured":"Morrissey C, Kostenuik P, Brown L, Vessella R, Corey E (2007) Host-derived RANKL is responsible for osteolysis in a C4-2 human prostate cancer xenograft model of experimental bone metastases. BMC Cancer 7(1):148","journal-title":"BMC Cancer"},{"issue":"24","key":"9279_CR10","doi-asserted-by":"crossref","first-page":"21352","DOI":"10.1074\/jbc.M111663200","volume":"277","author":"SL Dallas","year":"2002","unstructured":"Dallas SL, Rosser JL, Mundy GR, Bonewald LF (2002) Proteolysis of latent transforming growth factor-beta (TGF-beta)-binding protein-1 by osteoclasts. A cellular mechanism for release of TGF-beta from bone matrix. J Biol Chem 277(24):21352\u201321360","journal-title":"J Biol Chem"},{"issue":"2","key":"9279_CR11","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0092-8674(00)81569-X","volume":"93","author":"DL Lacey","year":"1998","unstructured":"Lacey DL, Timms E, Tan H-L, Kelley MJ, Dunstan CR, Burgess T et al (1998) Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93(2):165\u2013176","journal-title":"Cell"},{"issue":"2","key":"9279_CR12","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1002\/path.1199","volume":"198","author":"S Kitazawa","year":"2002","unstructured":"Kitazawa S, Kitazawa R (2002) RANK ligand is a prerequisite for cancer-associated osteolytic lesions. J Pathol 198(2):228\u2013236","journal-title":"J Pathol"},{"key":"9279_CR13","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/j.0105-2896.2005.00327.x","volume":"208","author":"S Tanaka","year":"2005","unstructured":"Tanaka S, Nakamura K, Takahasi N, Suda T (2005) Role of RANKL in physiological and pathological bone resorption and therapeutics targeting the RANKL-RANK signaling system. Immunol Rev 208:30\u201349","journal-title":"Immunol Rev"},{"issue":"1","key":"9279_CR14","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.ctrv.2007.09.002","volume":"34","author":"GD Roodman","year":"2008","unstructured":"Roodman GD, Dougall WC (2008) RANK ligand as a therapeutic target for bone metastases and multiple myeloma. Cancer Treat Rev 34(1):92\u2013101","journal-title":"Cancer Treat Rev"},{"issue":"10","key":"9279_CR15","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1172\/JCI11685","volume":"107","author":"J Zhang","year":"2001","unstructured":"Zhang J, Dai J, Qi Y, Lin DL, Smith P, Strayhorn C et al (2001) Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone. J Clin Invest 107(10):1235\u20131244","journal-title":"J Clin Invest"},{"issue":"22","key":"9279_CR16","first-page":"7883","volume":"63","author":"J Zhang","year":"2003","unstructured":"Zhang J, Dai J, Yao Z, Lu Y, Dougall W, Keller ET (2003) Soluble receptor activator of nuclear factor kappaB Fc diminishes prostate cancer progression in bone. Cancer Res 63(22):7883\u20137890","journal-title":"Cancer Res"},{"issue":"11","key":"9279_CR17","first-page":"4432","volume":"61","author":"S Morony","year":"2001","unstructured":"Morony S, Capparelli C, Sarosi I, Lacey DL, Dunstan CR, Kostenuik PJ (2001) Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastasis. Cancer Res 61(11):4432\u20134436","journal-title":"Cancer Res"},{"issue":"14","key":"9279_CR18","doi-asserted-by":"crossref","first-page":"5803","DOI":"10.1158\/0008-5472.CAN-07-5889","volume":"68","author":"TJ Wilson","year":"2008","unstructured":"Wilson TJ, Nannuru KC, Futakuchi M, Sadanandam A, Singh RK (2008) Cathepsin G enhances mammary tumor-induced osteolysis by generating soluble receptor activator of nuclear factor-{kappa}B ligand. Cancer Res 68(14):5803\u20135811","journal-title":"Cancer Res"},{"issue":"2","key":"9279_CR19","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.bbcan.2007.11.001","volume":"1785","author":"TJ Wilson","year":"2008","unstructured":"Wilson TJ, Singh RK (2008) Proteases as modulators of tumor\u2013stromal interaction: primary tumors to bone metastases. Biochimica et Biophysica Acta (BBA) Rev Cancer 1785(2):85\u201395","journal-title":"Biochimica et Biophysica Acta (BBA) Rev Cancer"},{"issue":"5","key":"9279_CR20","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.ccr.2005.04.013","volume":"7","author":"CC Lynch","year":"2005","unstructured":"Lynch CC, Hikosaka A, Acuff HB, Martin MD, Kawai N, Singh RK et al (2005) MMP-7 promotes prostate cancer-induced osteolysis via the solubilization of RANKL. Cancer Cell 7(5):485\u2013496","journal-title":"Cancer Cell"},{"issue":"25","key":"9279_CR21","doi-asserted-by":"crossref","first-page":"22331","DOI":"10.1074\/jbc.M302781200","volume":"278","author":"V Chesneau","year":"2003","unstructured":"Chesneau V, Becherer JD, Zheng Y, Erdjument-Bromage H, Tempst P, Blobel CP (2003) Catalytic properties of ADAM19. J Biol Chem 278(25):22331\u201322340","journal-title":"J Biol Chem"},{"issue":"18","key":"9279_CR22","doi-asserted-by":"crossref","first-page":"14665","DOI":"10.1074\/jbc.M010741200","volume":"276","author":"J Schlondorff","year":"2001","unstructured":"Schlondorff J, Lum L, Blobel CP (2001) Biochemical and pharmacological criteria define two shedding activities for TRANCE\/OPGL that are distinct from the tumor necrosis factor alpha convertase. J Biol Chem 276(18):14665\u201314674","journal-title":"J Biol Chem"},{"issue":"6","key":"9279_CR23","first-page":"1399","volume":"52","author":"CJ Aslakson","year":"1992","unstructured":"Aslakson CJ, Miller FR (1992) Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. Cancer Res 52(6):1399\u20131405","journal-title":"Cancer Res"},{"issue":"19","key":"9279_CR24","doi-asserted-by":"crossref","first-page":"9004","DOI":"10.1158\/0008-5472.CAN-05-0885","volume":"65","author":"Z Chen","year":"2005","unstructured":"Chen Z, Varney ML, Backora MW, Cowan K, Solheim JC, Talmadge JE et al (2005) Down-regulation of vascular endothelial cell growth factor-C expression using small interfering RNA vectors in mammary tumors inhibits tumor lymphangiogenesis and spontaneous metastasis and enhances survival. Cancer Res 65(19):9004\u20139011","journal-title":"Cancer Res"},{"issue":"5","key":"9279_CR25","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1186\/bcr77","volume":"2","author":"GH Heppner","year":"2000","unstructured":"Heppner GH, Miller FR, Shekhar PM (2000) Nontransgenic models of breast cancer. Breast Cancer Res 2(5):331\u2013334","journal-title":"Breast Cancer Res"},{"issue":"20","key":"9279_CR26","first-page":"5727","volume":"62","author":"X Huang","year":"2002","unstructured":"Huang X, Wong MK, Yi H, Watkins S, Laird AD, Wolf SF et al (2002) Combined therapy of local and metastatic 4T1 breast tumor in mice using SU6668, an inhibitor of angiogenic receptor tyrosine kinases, and the immunostimulator B7.2-IgG fusion protein. Cancer Res 62(20):5727\u20135735","journal-title":"Cancer Res"},{"issue":"2","key":"9279_CR27","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1023\/A:1006689719505","volume":"17","author":"M Lelekakis","year":"1999","unstructured":"Lelekakis M, Moseley JM, Martin TJ, Hards D, Williams E, Ho P et al (1999) A novel orthotopic model of breast cancer metastasis to bone. Clin Exp Metastasis 17(2):163\u2013170","journal-title":"Clin Exp Metastasis"},{"issue":"7","key":"9279_CR28","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1023\/A:1020958915361","volume":"19","author":"BO Murphy","year":"2002","unstructured":"Murphy BO, Joshi S, Kessinger A, Reed E, Sharp JG (2002) A murine model of bone marrow micrometastasis in breast cancer. Clin Exp Metastasis 19(7):561\u2013569","journal-title":"Clin Exp Metastasis"},{"issue":"47","key":"9279_CR29","doi-asserted-by":"crossref","first-page":"7893","DOI":"10.1038\/sj.onc.1208062","volume":"23","author":"EK Sloan","year":"2004","unstructured":"Sloan EK, Stanley KL, Anderson RL (2004) Caveolin-1 inhibits breast cancer growth and metastasis. Oncogene 23(47):7893\u20137897","journal-title":"Oncogene"},{"issue":"1","key":"9279_CR30","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0167-4781(99)00144-X","volume":"1489","author":"CF Bennett","year":"1999","unstructured":"Bennett CF, Cowsert LM (1999) Antisense oligonucleotides as a tool for gene functionalization and target validation. Biochim Biophys Acta 1489(1):19\u201330","journal-title":"Biochim Biophys Acta"},{"issue":"10","key":"9279_CR31","first-page":"1444","volume":"2","author":"SP Henry","year":"2001","unstructured":"Henry SP, Geary RS, Yu R, Levin AA (2001) Drug properties of second-generation antisense oligonucleotides: how do they measure up to their predecessors? Curr Opin Invest Drugs 2(10):1444\u20131449","journal-title":"Curr Opin Invest Drugs"},{"issue":"10","key":"9279_CR32","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1158\/1535-7163.MCT-07-0234","volume":"6","author":"LA Kingsley","year":"2007","unstructured":"Kingsley LA, Fournier PGJ, Chirgwin JM, Guise TA (2007) Molecular biology of bone metastasis. Mol Cancer Ther 6(10):2609\u20132617","journal-title":"Mol Cancer Ther"},{"issue":"4","key":"9279_CR33","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s10555-006-9023-1","volume":"25","author":"VA Siclari","year":"2006","unstructured":"Siclari VA, Guise TA, Chirgwin JM (2006) Molecular interactions between breast cancer cells and the bone microenvironment drive skeletal metastases. Cancer Metastasis Rev 25(4):621\u2013633","journal-title":"Cancer Metastasis Rev"},{"issue":"1","key":"9279_CR34","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/ncponc0381","volume":"3","author":"JM Blair","year":"2006","unstructured":"Blair JM, Zhou H, Seibel MJ, Dunstan CR (2006) Mechanisms of disease: roles of OPG, RANKL and RANK in the pathophysiology of skeletal metastasis. Nat Clin Pract Oncol 3(1):41\u201349","journal-title":"Nat Clin Pract Oncol"},{"issue":"14","key":"9279_CR35","doi-asserted-by":"crossref","first-page":"6130","DOI":"10.1158\/0008-5472.CAN-04-1408","volume":"65","author":"C Kuperwasser","year":"2005","unstructured":"Kuperwasser C, Dessain S, Bierbaum BE, Garnet D, Sperandio K, Gauvin GP et al (2005) A mouse model of human breast cancer metastasis to human bone. Cancer Res 65(14):6130\u20136138","journal-title":"Cancer Res"},{"issue":"2","key":"9279_CR36","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1359\/jbmr.2003.18.2.190","volume":"18","author":"AH Reddi","year":"2003","unstructured":"Reddi AH, Roodman D, Freeman C, Mohla S (2003) Mechanisms of tumor metastasis to the bone: challenges and opportunities. J Bone Miner Res 18(2):190\u2013194","journal-title":"J Bone Miner Res"},{"key":"9279_CR37","doi-asserted-by":"crossref","unstructured":"Varney ML, Singh S, Backora M, Chen Z, Singh RK (2008) Lymphangiogenesis and anti-tumor immune responses. Curr Mol Med (In Press)","DOI":"10.2174\/156652409788970733"},{"issue":"5","key":"9279_CR38","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1016\/S0002-9440(10)63560-2","volume":"163","author":"E Grimaud","year":"2003","unstructured":"Grimaud E, Soubigou L, Couillaud S, Coipeau P, Moreau A, Passuti N et al (2003) Receptor activator of nuclear factor kappaB ligand (RANKL)\/osteoprotegerin (OPG) ratio is increased in severe osteolysis. Am J Pathol 163(5):2021\u20132031","journal-title":"Am J Pathol"},{"issue":"6 Pt 1","key":"9279_CR39","doi-asserted-by":"crossref","first-page":"2302","DOI":"10.1097\/01.ju.0000094191.39574.cb","volume":"170","author":"K Jung","year":"2003","unstructured":"Jung K, Stephan C, Semjonow A, Lein M, Schnorr D, Loening SA (2003) Serum osteoprotegerin and receptor activator of nuclear factor-kappa B ligand as indicators of disturbed osteoclastogenesis in patients with prostate cancer. J Urol 170(6 Pt 1):2302\u20132305","journal-title":"J Urol"},{"issue":"7","key":"9279_CR40","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1182\/blood.V98.7.2269","volume":"98","author":"C Seidel","year":"2001","unstructured":"Seidel C, Hjertner O, Abildgaard N, Heickendorff L, Hjorth M, Westin J et al (2001) Serum osteoprotegerin levels are reduced in patients with multiple myeloma with lytic bone disease. Blood 98(7):2269\u20132271","journal-title":"Blood"},{"issue":"3","key":"9279_CR41","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1182\/blood-2003-02-0380","volume":"102","author":"E Terpos","year":"2003","unstructured":"Terpos E, Szydlo R, Apperley JF, Hatjiharissi E, Politou M, Meletis J et al (2003) Soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index. Blood 102(3):1064\u20131069","journal-title":"Blood"},{"issue":"6","key":"9279_CR42","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/BF00133470","volume":"10","author":"PJ Kostenuik","year":"1992","unstructured":"Kostenuik PJ, Singh G, Suyama KL, Orr FW (1992) Stimulation of bone resorption results in a selective increase in the growth rate of spontaneously metastatic Walker 256 cancer cells in bone. Clin Exp Metastasis 10(6):411\u2013418","journal-title":"Clin Exp Metastasis"},{"issue":"4","key":"9279_CR43","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1210\/en.2004-1211","volume":"146","author":"A Schneider","year":"2005","unstructured":"Schneider A, Kalikin LM, Mattos AC, Keller ET, Allen MJ, Pienta KJ et al (2005) Bone turnover mediates preferential localization of prostate cancer in the skeleton. Endocrinology 146(4):1727\u20131736","journal-title":"Endocrinology"},{"issue":"1","key":"9279_CR44","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1093\/jnci\/dji002","volume":"97","author":"JE Brown","year":"2005","unstructured":"Brown JE, Cook RJ, Major P, Lipton A, Saad F, Smith M et al (2005) Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. JNCI J Natl Cancer Inst 97(1):59\u201369","journal-title":"JNCI J Natl Cancer Inst"},{"issue":"3","key":"9279_CR45","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1200\/JCO.2002.20.3.850","volume":"20","author":"L Costa","year":"2002","unstructured":"Costa L, Demers LM, Gouveia-Oliveira A, Schaller J, Costa EB, de Moura MC et al (2002) Prospective evaluation of the peptide-bound collagen type I cross-links N-telopeptide and C-telopeptide in predicting bone metastases status. J Clin Oncol 20(3):850\u2013856","journal-title":"J Clin Oncol"},{"issue":"16","key":"9279_CR46","first-page":"3551","volume":"55","author":"A Sasaki","year":"1995","unstructured":"Sasaki A, Boyce BF, Story B, Wright KR, Chapman M, Boyce R et al (1995) Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice. Cancer Res 55(16):3551\u20133557","journal-title":"Cancer Res"},{"issue":"17","key":"9279_CR47","doi-asserted-by":"crossref","first-page":"7682","DOI":"10.1158\/0008-5472.CAN-04-4188","volume":"65","author":"G Pluijm van der","year":"2005","unstructured":"van der Pluijm G, Que I, Sijmons B, Buijs JT, Lowik CWGM, Wetterwald A et al (2005) Interference with the microenvironmental support impairs the de novo formation of bone metastases in vivo. Cancer Res 65(17):7682\u20137690","journal-title":"Cancer Res"},{"key":"9279_CR48","doi-asserted-by":"crossref","unstructured":"Buijs JT, Que I, Lowik CW, Papapoulos SE, Van der Pluijm G (2009) Inhibition of bone resorption and growth of breast cancer in the bone microenvironment. Bone 44(2):380\u2013386","DOI":"10.1016\/j.bone.2008.10.047"},{"issue":"5","key":"9279_CR49","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1158\/1078-0432.CCR-05-1806","volume":"12","author":"PA Phadke","year":"2006","unstructured":"Phadke PA, Mercer RR, Harms JF, Jia Y, Frost AR, Jewell JL et al (2006) Kinetics of metastatic breast cancer cell trafficking in bone. Clin Cancer Res 12(5):1431\u20131440","journal-title":"Clin Cancer Res"},{"issue":"32","key":"9279_CR50","doi-asserted-by":"crossref","first-page":"8219","DOI":"10.1200\/JCO.2005.02.9579","volume":"23","author":"MD Michaelson","year":"2005","unstructured":"Michaelson MD, Smith MR (2005) Bisphosphonates for treatment and prevention of bone metastases. J Clin Oncol 23(32):8219\u20138224","journal-title":"J Clin Oncol"},{"issue":"7","key":"9279_CR51","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1080\/02841860410032885","volume":"43","author":"T Saarto","year":"2004","unstructured":"Saarto T, Vehmanen L, Virkkunen P, Blomqvist C (2004) Ten-year follow-up of a randomized controlled trial of adjuvant clodronate treatment in node-positive breast cancer patients. Acta Oncol 43(7):650\u2013656","journal-title":"Acta Oncol"}],"container-title":["Clinical &amp; Experimental Metastasis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10585-009-9279-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10585-009-9279-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10585-009-9279-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,30]],"date-time":"2019-05-30T18:39:47Z","timestamp":1559241587000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10585-009-9279-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,7,10]]},"references-count":51,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2009,10]]}},"alternative-id":["9279"],"URL":"https:\/\/doi.org\/10.1007\/s10585-009-9279-2","relation":{},"ISSN":["0262-0898","1573-7276"],"issn-type":[{"value":"0262-0898","type":"print"},{"value":"1573-7276","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,7,10]]}}}